OncoPharm

Talking 3rd-line treatment of metastatic colon cancer. Tipiracil-trifluridine + bevacizuamb vs. tipiracil-trifluridine alone. And a bit on the theory of "bevacizumab beyond progression."

SUNLIGHT: https://www.nejm.org/doi/full/10.1056/NEJMoa2214963

Quizartinib vs. Placebo(?) + Chemo in newly diagnosed AML.

We add a bit of context about quizartinib's history leading up to this study preview possible role in therapy if approved in the future.

Link: https://doi.org/10.1016/S0140-6736(23)00464-6

We take a peak at an intriguing study (n = 29) that gave some metastatic RCC patients receiving nivolumab + ipilimumab a supplement of a bacterium (n = 19) and a control group.

We discuss what to look for in the future studies that are likely to follow with similar methods.

The Landmarks of OncoPharm series returns to discuss NSABP's B18 story of neoadjuvant vs. adjuvant AC in stages I & II breast cancer from 1998.

B18: https://pubmed.ncbi.nlm.nih.gov/?term=36989610

Flashback Flashforeward: https://pubmed.ncbi.nlm.nih.gov/?term=36989608

Lots of updates:

Olanzapine increases weight gain, QOL in some advanced cancer: https://pubmed.ncbi.nlm.nih.gov/?term=36977285

Chemotherapy Toxicity - When Less is More: https://www.nejm.org/doi/full/10.1056/NEJMcibr1202395

Pembro + Chemo improves PFS > chemo alone in advanced endometrial cancer: https://www.nejm.org/doi/full/10.1056/NEJMoa2302312

Enfortumab vedotin + pembrolizumab gets an accelerated approval for cisplatin-ineligible patients with urothelial carcinoma. Safety signals seen.

With new Pod this week, we're re-releasing the 2nd episode from way back in 2017 that provides a historical overview of how the use of EGFR TKIs changed from their use in all NSLCLC to only with activating mutations.

Not that you always need extended gram positive coverage, but if you did...

As is often the case with this Pod, this is mostly providing historical context.

Link: https://doi.org/10.1086/500139

Prompted by a recent JCO review article (link below), it seemed like a good idea to discuss risks of ovarian dysfunction in women of childbearing potential, what drugs have the highest risk, and fertility preservation techniques.

Review article: https://pubmed.ncbi.nlm.nih.gov/?term=29620997

Cyclophosphamide dose equivalent calculator: https://www.oncofertilityrisk.com/CED.html

We review a clever study looking at neoadjvuant & adjuvant pembrolizumab vs. only adjuvant pembrolizumab in melanoma.

Link: 10.1056/NEJMoa2211437

We also discuss some updates on abemaciclib and osimertinib

Landkarmks of OncoPharm: Dose-Adjusted EPOCH (+ R)

This episode focuses on the pharmacodynamic rationale for the protocol and delivery, not so much the details of the literature supporting its use.

Wilson et al 2002, Blood: https://doi.org/10.1182/blood.V99.8.2685